The probe is directed at all CAR-Ts currently ... positive lymphoma – in patients who had received both types of CAR-T therapy. The regulator highlighted the products by name, including Bristol- ...

Neuroblastoma (NB), a cancer arising in the adrenal gland or less often from the extra-adrenal sympathetic chain, including in the retroperitoneum, chest, and neck, represents the most common solid ...

When the symptoms and inflammation are not brought under control, they can cause organ damage. Like other cell therapies, CAR T cell therapy uses a modified cell either from the patient or from a ...

Like other CAR-Ts, Calibr's therapy is manufactured from a patient's own T-cells, which are harvested and genetically modified to fight cancer before being reintroduced into the body. However ...

CAR T-cell therapy carried a risk of second primary malignancy (SPM) that was no worse than that of other standard-of-care (SOC) cancer therapies, according to a systematic literature review and ...

Chimeric antigen receptor T-cell therapy, or CAR-T cell therapy, is one type of immunotherapy. Sometimes likened to a “smart drug” or “living drug,” CAR-T cell therapy relies on ...

The frequency of second primary malignancies (SPMs) arising in cancer survivors following treatment with CAR T-cell therapy was statistically comparable to the frequency of SPMs following other ...

The frequency of second primary malignancies (SPMs) arising in cancer survivors following treatment with CAR T-cell therapy was statistically comparable to the frequency of SPMs following other ...

In a new study, researchers examined the efficacy and impact of CD19 CAR T cell therapy on B cells, specifically exploring its ability to deplete B cells in deep tissues and understand the therapeutic ...

CAR-T cell therapy is moving to earlier lines of multiple myeloma treatment. Elouise Wrisper’s cancer journey began with persistent back pain. It was 2021, and the retired teacher, who was active in ...

A case report highlights a rare instance of parkinsonism following CAR T-cell therapy for multiple myeloma. While immune effector cell-associated neurotoxicity affects up to 40% of patients with ...

The cars had striking, futuristic bodywork and enough '80s tech to make E.T. jealous. The Ford Probe I’s owner recently brought the car to Monterey Car Week, but it didn’t make it home in one ...